Turn Therapeutics
Westlake Village, US
Turn Therapeutics develops topical therapies for skin diseases using its proprietary PermaFusion drug delivery platform. The company's lead program, GX-03, is designed to treat moderate to severe eczema by reducing IL-36 signaling and downstream inflammatory cytokines.
Founders & leadership
BB
Bradley BurnamChief Executive Officer
ZC
Zuraiz ChaudharyExecutive
NS
Neilesh Shailesh GhodadraExecutive
Board
MW
Martin William DewhurstBoard director
AG
Andrew GengosBoard director
AF
Arthur F GoldenBoard director
KK
Kent KesterBoard director
Reported raises · per SEC filings
Form D private placements$1.6M disclosed across 1 round · 2026
▶$1.6MraisedAug 2026 · 8 investors · BiotechnologyRule 506(b)
▶$1.6MraisedAug 2026 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bradley BurnamExecutive Officer, Director
- Zuraiz ChaudharyExecutive Officer
- Martin William DewhurstDirector
- Andrew GengosDirector
- Arthur F GoldenDirector
- Kent KesterDirector
- Neilesh Shailesh GhodadraExecutive Officer, Director
- Amount sold
- $1.6M
- Minimum investment
- $15K
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Turn Therapeutics do?
- Turn Therapeutics develops topical therapies for skin diseases using its proprietary PermaFusion drug delivery platform. The company's lead program, GX-03, is designed to treat moderate to severe eczema by reducing IL-36 signaling and downstream inflammatory cytokines.
- Who founded Turn Therapeutics?
- Turn Therapeutics was founded by Bradley Burnam.
- How much funding has Turn Therapeutics raised?
- Turn Therapeutics has disclosed $1.6M raised across 1 round.
- Where is Turn Therapeutics headquartered?
- Turn Therapeutics is headquartered in Westlake Village, US.